March 10, 2021

SARS-CoV-2 501Y.V2 (B.1.351) Elicits Cross-Reactive Neutralizing Antibodies

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, variants

• [Pre-print, not peer-reviewed] Antibody responses to the 501Y.V2 SARS-CoV-2 variant in a cohort of patients hospitalized with COVID-19 in South Africa (n = 89) were found to be robust and showed high levels of cross-reactivity against the virus strain from the first wave. Furthermore, sera from patients infected with 501Y.V2 also neutralized the 501Y.V3 (P.1) variant first described in Brazil, suggesting that the antibody response in patients infected with 501Y.V2 has broad specificity. 

Moyo-Gwete et al. (Mar 6, 2021). SARS-CoV-2 501Y.V2 (B.1.351) Elicits Cross-Reactive Neutralizing Antibodies. Pre-print downloaded Mar 10 from https://doi.org/10.1101/2021.03.06.434193